| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8757998 | European Journal of Internal Medicine | 2018 | 8 Pages |
Abstract
Prescription of ACE (or ARB) inhibitors and β-blockers for patients with HFREF may be low despite the evidence for morbidity and mortality improvement with these medications but remains associated with reduced 1-year mortality in unselected HFREF patients.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Amandine Busson, Nathalie Thilly, Hervé Laborde-Castérot, François Alla, Ziyad Messikh, Isabelle Clerc-Urmes, Alexandre Mebazaa, Marc Soudant, Nelly Agrinier,